Immune Genes Linked to Tumor Risk in NF1
Original title: Human leucocyte antigen class I and II alleles are associated with tumor susceptibility in neurofibromatosis type 1.
How far along is this research?
- Lab cells
- Animals
- Review
- Tested in people
This was tested in people. That is the most reliable kind of research we share.
This was seen in gene data from people, but it still needs to be checked in a new study.
The short version
Certain immune genes may help show which people with NF1 face a higher tumor risk.
What was studied. Researchers checked immune system genes, called HLA genes, in people with NF1 tumors. They looked at 38 people with high grade glioma: A tumor that starts in the glial cells. Those are the support cells of the brain and spinal cord. Gliomas are given a grade from 1 to 4. The grade says how the tumor is expected to act. See the glossary and 91 with low grade glioma. They also looked at 105 people with a nerve tumor called MPNST.
What they found. Certain HLA genes lined up with certain NF1 tumor types. One gene version, called HLA-B*40:02, was tied to MPNST. Lifetime risk of MPNST is usually 10 to 15.8%. In people with this gene version, the risk was about 36.6%.
What this means, and what it doesn't
What it could mean: One day a gene test might show who needs closer watching. Doctors could then screen some people more often. That kind of test is not part of NF1 care today.
What it doesn't mean: This is not a new treatment, and it is not a cure. The study looked back at gene data from people who already had tumors. The authors say the results must be checked in a new group of people. Carrying one of these genes does not mean a tumor will happen. This is early research, and it is still far from everyday care.
Source: PubMed, October 19, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.